A small Oct. 6 study from the National Institutes of Health found that a longer course of Pfizer’s COVID-19 treatment was not more effective than its recommended five-day regimen.
Read the full post on Becker's Hospital Review - Healthcare News
Longer Paxlovid course doesn’t reduce risk of rebound, study finds
